This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US Supreme Court could rethink induced infringement with ‘skinny label’ case

By Nick Robertson ( April 23, 2026, 16:46 GMT | Comment) -- The US Supreme Court is set to hear oral arguments in Hikma Pharmaceuticals v. Amarin Pharma next week over what constitutes induced patent infringement for generic medications sold with a so-called “skinny label.” Experts tell MLex that the case could be an opportunity for the court to set new, clear boundaries for inducement claims, with potentially significant ramifications.Oral arguments in Hikma Pharmaceuticals v. Amarin Pharma before the US Supreme Court next week could show if the court is willing to rethink the bounds of induced patent infringement, experts tell MLex....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login